dr. o’malley on the state of immunotherapy in ovarian cancer
Published 4 years ago • 152 plays • Length 1:08Download video MP4
Download video MP3
Similar videos
-
1:09
dr. o’malley on research with immunotherapy in ovarian cancer
-
1:35
dr. o’malley on ongoing clinical trials evaluating immunotherapy in ovarian cancer
-
0:58
dr. o’malley on the utility of mirvetuximab in ovarian cancer
-
1:15
dr. o’malley on the safety profile of mirvetuximab in ovarian cancer
-
1:00
dr. o’malley on the forward ii phase ib study in ovarian cancer
-
1:47
dr. o’malley on antitumor activity with veliparib combo in serous ovarian cancer
-
1:10
dr. o'malley on fda approval of maintenance rucaparib in ovarian cancer
-
27:10
promising advances in low grade serous ovarian cancer
-
1:54
dr. o’malley on maintenance rucaparib in non-brca hrr-mutated in ovarian cancer
-
1:15
dr. o’malley on remaining questions in ovarian cancer
-
1:18
dr. o'malley on the tolerability of parp inhibitors in ovarian cancer
-
0:58
dr. o’malley on the optimal use of parp inhibitors in advanced ovarian cancer
-
1:34
dr. moore on challenges with immunotherapy in ovarian cancer
-
27:23
breakthroughs in immunotherapy in ovarian cancer
-
1:35
dr. coleman on immunotherapy in ovarian cancer
-
0:50
dr. emens on the future of immunotherapy in ovarian cancer
-
0:51
dr. o'malley on folate-receptor alpha as a biomarker in ovarian cancer
-
1:11
dr. o'malley on toxicity profiles of parp inhibitors in ovarian cancer
-
0:34
improving immunotherapy for the treatment of patients with ovarian cancer